Table 1 Patients’ characteristics
| Â | Control | Tomotherapy |
|---|---|---|
|  | n = 32 | n = 37 |
Age | Â | Â |
 <50 | 10 | 15 |
 > = 50 | 22 | 22 |
Left breast tumor | 16 | 24 |
Medial location | 12 | 8 |
Tumor size | Â | Â |
 T1 (<= 20 mm) | 21 | 26 |
 T2 (21–50 mm) | 11 | 11 |
Nodal status, Lymph node ratio | Â | Â |
 pN0 | 21 | 24 |
 pN1, LNR 0.01-0.20 | 7 | 12 |
 pN1, LNR 0.21-0.65 | 4 | 1 |
 pN1, LNR > 0.65 | 0 | 0 |
Estrogen receptor positive | 28 | 27 |
Progesterone receptor positive | 21 | 25 |
HER2 FISH amplified | 2 | 8 |
Histological grade | Â | Â |
 1 | 11 | 11 |
 2 | 8 | 18 |
 3 | 10 | 8 |
 unknown | 3 | 0 |
Surgery | Â | Â |
 Breast conserving | 21 | 20 |
Axillary lymph nodes | Â | Â |
 Sentinel biopsy only | 20 | 17 |
 Sentinel with axillary dissection | 4 | 6 |
 Immediate axillary dissection | 8 | 14 |
Radio-chemotherapy schedule | Â | Â |
 No adjuvant chemotherapy | 18 | 17 |
 RT after completion of chemotherapy | 3 | 5 |
 RT concomitant with start chemotherapy | 11 | 15 |
Chemotherapy type | Â | Â |
 Anthracycline without taxane | 3 | 4 |
 Anthracycline with taxane | 10 | 15 |
 CMF | 1 | 1 |
Hormone therapy | Â | Â |
 No hormone therapy | 4 | 10 |
 Tamoxifen | 15 | 11 |
 Letrozole | 13 | 11 |
 Zoladex | 0 | 1 |
 Tamoxifen + Zoladex | 0 | 4 |
 Trastuzumab | 2 | 8 |